Advertisement

Reproductive Depression and the Response to Hormone Therapy

  • John W. StuddEmail author
  • Mike Savvas
  • Neale Watson
Chapter
Part of the ISGE Series book series (ISGE)

Abstract

Many cases of depression in women are due to endocrine factors and inappropriate treatment by antidepressants or mood-stabilizing drugs such as lithium. The syndrome reproductive depression includes premenstrual depression (PMDD), postnatal depression (PND) and climacteric depression which is more severe in the transitional phase 2 or 3 years before the periods cease rather than in the years after the menopause. Such patients are usually free of depression during pregnancy. The diagnosis cannot be made by measuring hormone levels but by a careful history relating depression to monthly cycles and the postnatal state. The range and aetiology of depression in women is different than in men and cannot be understood without knowledge of the effect that oestrogen, progesterone and androgens have upon mood. These frequent problems are usually treated badly by psychiatrists who have little knowledge and less interest in the effect of hormones on mood. Treatment should be by oestrogens preferably by the transdermal route possibly with the addition of testosterone and if necessary the addition of progesterone to protect the endometrium.

References

  1. 1.
    Dickens C. Household words, vol. 95. New York, NY: D. Appleton; 1852. p. 385–9.Google Scholar
  2. 2.
    Studd J. A guide to hormone therapy for the treatment of depression in women. Climacteric. 2011;14:637–42.CrossRefGoogle Scholar
  3. 3.
    Studd J, Nappi RE. Reproductive Depression. Gynecol Endocrinol. 2012;28(Suppl 1):42–5.CrossRefGoogle Scholar
  4. 4.
    Nappi RE, Tonani S, Santamaria V, Ornati A, Albani F, Pisani C, Polatti F. Luteal phase dysphoric disorder and premenstrual syndrome. It J Psych. 2009;28:27–33.Google Scholar
  5. 5.
    Burger HG, Hale GE, Robertson DN, Dennerstein L. A review of hormonal changes during the menopausal transition. Hum Reprod Update. 2007;13:559–65.CrossRefGoogle Scholar
  6. 6.
    Craig MC. Should psychiatrist be prescribing oestrogen therapy to their patients? Br J Psychiatry. 2013;202(1):9–13.CrossRefGoogle Scholar
  7. 7.
    Ismaili E, Walsh S, O’Brien PMS, et al. Fourth consensus of the international society of premenstrual disorders (ISPMD): auditable standards for the diagnosis and management of premenstrual disorder. Arch Womens Ment Health. 2016;19(6):953–8.CrossRefGoogle Scholar
  8. 8.
    Wessel Skovlund C, Steinrud Morch L, Vedel Kessing L, Liddegaard O. Association of hormonal contraception with depression. JAMA Psychiat. 2016;73(11):1154–62.CrossRefGoogle Scholar
  9. 9.
    Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update. 1997;3:159–71.CrossRefGoogle Scholar
  10. 10.
    Watson NR, Studd JWW, Savvas M, Garnett T, Baber RJ. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet. 1989;8665:730–2.CrossRefGoogle Scholar
  11. 11.
    Elovainio M, Teperi J, Aalto AM. Depressive symptoms as predictors of discontinuation of levonorgestrel releasing intrauterine system. Int J Behav Med. 2007;14:70–5.CrossRefGoogle Scholar
  12. 12.
    Leather AT, Studd JW, Watson NR, Holland EF. The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: a placebo-controlled study. Gynecol Endocrinol. 1999;13:48–55.CrossRefGoogle Scholar
  13. 13.
    Leather AT, Studd JWW, Watson NR, Holland EFN. The prevention of bone loss in young women treated with GnRh analogues with ‘add back’ oestrogen therapy. Obstet Gynecol. 1993;81:104–7.PubMedGoogle Scholar
  14. 14.
    Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O’Brien PM. The effectiveness of GnRH analogue with and without “addback” therapy in treating premenstrual syndrome: a meta analysis. BJOG. 2004;111:585–93.CrossRefGoogle Scholar
  15. 15.
    Di Carlo C, Palomba S, GAm T, et al. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril. 2001;76:850–2.CrossRefGoogle Scholar
  16. 16.
    Casson P, Hahn PM, Van Vugt DA, Reed RL. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am Obstet Gynecol. 1990;162:99–105.CrossRefGoogle Scholar
  17. 17.
    Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod. 2004;19:2152–5.CrossRefGoogle Scholar
  18. 18.
    Studd J. Severe premenstrual syndrome and bipolar disorder; a frequent tragic confusion. Menopause Int. 2012;18:65–7.CrossRefGoogle Scholar
  19. 19.
    Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018;1:68–74.CrossRefGoogle Scholar
  20. 20.
    Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000;157:924–30.CrossRefGoogle Scholar
  21. 21.
    Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal estrogen for the treatment of severe post-natal depression. Lancet. 1996;347:930–3.CrossRefGoogle Scholar
  22. 22.
    Dennis CL, Ross LE, Herxheimer A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst Rev. 2008;4:CD001690.Google Scholar
  23. 23.
    Dennerstein L, Lehert P, Burger H, et al. Mood and the menopausal transition. J Nerv Ment Dis. 1999;187:685–91.CrossRefGoogle Scholar
  24. 24.
    Brincat M, Magos A, Studd JW, et al. Subcutaneous hormone implants for the control of climacteric symptoms. A prospective study. Lancet. 1984;1:16–8.CrossRefGoogle Scholar
  25. 25.
    Soares CN, Almeida JH, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529–34.CrossRefGoogle Scholar
  26. 26.
    Montgomery JC, Brincat M, Tapp A, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet. 1987;1:297–9.CrossRefGoogle Scholar
  27. 27.
    Studd J. HRT should be considered as first line therapy for perimenopausal depression: FOR: estrogens are the first line treatment for perimenopausal women. BJOG. 2016;123:1011.CrossRefGoogle Scholar
  28. 28.
    Craig MC. HRT should be considered as first line therapy for perimenopausal depression: against: more clinical trials are needed. BJOG. 2016;123:1011.CrossRefGoogle Scholar
  29. 29.
    Gath D, Rose N, Bond A, et al. Hysterectomy and psychiatric disorder. Psychol Med. 1995;25:277–83.CrossRefGoogle Scholar
  30. 30.
    Khastgir G, Studd J. Patient’s outlook experience and satisfaction with hysterectomy bilateral oophorectomy and subsequent hormone replacement therapy. Am J Obstet Gynecol. 2000;183:1427–33.CrossRefGoogle Scholar
  31. 31.
    Studd J. Hysterectomy A life saving as well life enhancing operation. Menopause Int. 2009;15:2–3.CrossRefGoogle Scholar
  32. 32.
    Graziottin A, Serafini A. Depression and the menopause: why antidepressants are not enough? Menopause Int. 2009;15:76–81.CrossRefGoogle Scholar
  33. 33.
    Studd J. Hormone therapy for reproductive depression in women. Post Reprod Health. 2014;20(4):132–7.CrossRefGoogle Scholar

Copyright information

© International Society of Gynecological Endocrinology 2019

Authors and Affiliations

  1. 1.London PMS and Menopause CentreLondonUK
  2. 2.King’s College HospitalLondonUK
  3. 3.Hillingdon HospitalMiddlesexUK

Personalised recommendations